Halozyme granted ViroPharma exclusive, worldwide rights to use its Enhanze recombinant human hyaluronidase (rHuPH20) drug delivery technology to develop a subcutaneous formulation of Cinryze

Halozyme Therapeutics Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

ViroPharma Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced